Medication info

Seoul Pregabalin Capsule 75 mg

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Seoul Pharmaceutical Co., Ltd.
Appearance
Hard capsule with a reddish-brown upper part and a white lower part, containing white or pale yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 201902310 · Approved 2019.04.16

This product's status changed to Expired on 2024.04.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this medicine is primarily eliminated by the kidneys, the dose must be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. Administer an initial dose of 75 mg twice daily (150 mg daily); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Although clinical studies were also conducted at a dose of 600 mg daily, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily eliminated by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration schedule / Initial dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12 ~17 years; therefore, administration is not recommended.

Ingredients

Manufacturer
Seoul Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalized symptoms
  • focal seizures
  • fibromyalgia
View approved original text

This medication is used in adults to treat peripheral and central neuropathic pain and as an adjunct for focal seizures in epilepsy. It is also effective in alleviating symptoms of fibromyalgia. In summary, this drug is used for the relief of peripheral and central neuropathic pain, adjunctive treatment of focal seizures in epilepsy, and improvement of fibromyalgia symptoms.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this medicine is primarily eliminated by the kidneys, the dose must be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. Administer an initial dose of 75 mg twice daily (150 mg daily); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Although clinical studies were also conducted at a dose of 600 mg daily, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily eliminated by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration schedule / Initial dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12 ~17 years; therefore, administration is not recommended.

Precautions

This medication is an antiepileptic drug, and during treatment, there may be changes in mood and behavior, such as suicidal thoughts or actions, depression, and abnormal mood changes that should be carefully monitored. Patients with allergies to any ingredients in this medication or certain genetic metabolic disorders such as lactose intolerance should not take it. Diabetic patients may experience changes in blood sugar control due to weight gain, thus adjustments in the dosage of antidiabetic medications may be necessary. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients should take extra care during the initial phase of treatment due to an increased risk of falls from dizziness or drowsiness. Temporary blurriness or changes in vision may occur with this medication; if symptoms persist, consultation with a healthcare professional is recommended. Long-term use or sudden discontinuation may result in withdrawal symptoms such as insomnia, headache, and anxiety; dosing should be done according to medical advice. When taken with other medications that may affect the central nervous system, there is a risk of drug misuse or dependency, requiring careful history taking and monitoring. Patients with impaired kidney function may need dose adjustments, and those with cardiovascular diseases should also take this medication cautiously. Caution is advised when used with opioid analgesics as there is an increased risk of central nervous system depression, and patients with respiratory or neurological diseases may require special care. Pregnant women are recommended to avoid this medication during early pregnancy due to potential effects on the fetus, and women of childbearing age should use effective contraception. Nursing mothers should consult with a healthcare professional regarding whether to continue breastfeeding or discontinue this medication since it may pass into breast milk. Activities requiring mental alertness, such as driving or operating machinery, should be avoided until dizziness and drowsiness from this medication have resolved. In the case of overdose, symptoms of confusion, drowsiness, and depression may occur, necessitating immediate medical attention for appropriate treatment. Keep out of reach of children and do not transfer medications to other containers.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial edema
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 191 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • pain
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • reduced oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • urinary retention
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • dysesthesia
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood swings
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • impaired coordination
  • balance dysfunction
  • amnesia
  • attention disorder
  • memory disorder
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • hepatitis myoclonus
  • reduced reflexes
  • motor disturbances
  • psychomotor agitation
  • positional vertigo
  • perceptual hyperesthesia
  • burning sensation
  • activity tremors
  • syncope
  • stupor
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eyelid edema
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during shaking
  • changes in depth perception
  • strabismus
  • brightness of vision
  • dizziness
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • homonymous bradycardia
  • homonymous tachycardia
  • homonymous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • agitation
  • restlessness
  • seizures
  • exacerbation of spasms
  • bloody stools
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to keep the storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsule with a reddish-brown upper part and a white lower part, containing white or pale yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.